FORTIS HEALTHCARE LTD.

Fortis Healthcare Limited held its 30th Annual General Meeting (AGM) on August 11, 2026, via Video Conferencing. The meeting, chaired by Mr. Leo Puri, addressed the adoption of Audited Financial Statements for FY26, declaration of a final dividend of ₹1 per equity share, and the re-appointment of directors retiring by rotation. Special business included ratification of Cost Auditors' remuneration and approval for commission to Independent Directors. The company also discussed the re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director & CEO. E-voting facilities were provided to shareholders.

Fortis Healthcare Ltd announced the appointment of M/s. B S R & Co. LLP, Chartered Accountants, as the company's Tax Auditors for the Financial Year 2025-26. This decision was approved by the Board of Directors during a meeting held on August 06, 2026. The board also approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report from the statutory auditors. B S R & Co. LLP is a well-established firm with extensive experience, auditing various listed companies in India, including those in the healthcare sector.

Fortis Healthcare Ltd's Board of Directors, in a meeting held on August 6, 2026, approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also announced the appointment of M/s. B S R & Co. LLP as Tax Auditors for the Financial Year 2025-26. The limited review report from the statutory auditors, M/s. B S R & Co. LLP, was also enclosed with the financial results. A certificate regarding compliance with financial covenants was also provided. The board meeting commenced at 12:00 Noon IST and concluded at 6:45 PM IST.

Agilus Diagnostics Limited, a material subsidiary of Fortis Healthcare Ltd, announced today that its Board of Directors has approved an intra-group restructuring. This involves the merger of its wholly-owned subsidiaries, Agilus Pathlabs Private Limited and DDRC Agilus Pathlabs Limited, into Agilus Diagnostics Limited via a Scheme of Arrangement. The merger is subject to approvals from the National Company Law Tribunals (NCLTs) and the companies' members and creditors. As this is an intra-group restructuring, no consideration will be payable.

Fortis Healthcare Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item for this meeting is to consider and approve the Un-audited Financial Results, both standalone and consolidated, for the first quarter ended June 30, 2026. Additionally, the company confirmed that the trading window for its securities will remain closed until 48 hours after the declaration of these financial results, extending up to August 8, 2026, in line with SEBI regulations.

Fortis Healthcare Ltd has announced a recommended final dividend of ₹1 per equity share for the financial year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming AGM on August 11, 2026. The dividend payment will be subject to Tax Deducted at Source (TDS) as per the Income Tax Act, 2025. Shareholders are urged to update their details, including PAN and residential status, by July 24, 2026 (Record Date) to ensure correct TDS application. Those seeking exemption or lower tax deduction must submit necessary declarations by August 5, 2026, via the provided web link or email.

Agilus Diagnostics Limited, a subsidiary of Fortis Healthcare Ltd, has appointed Vijender Singh as its new Managing Director and Chief Executive Officer, effective July 20, 2026. Singh brings over three decades of leadership experience in diagnostics, healthcare, and FMCG sectors, having previously held senior roles at Diagnum Healthcare, Metropolis Healthcare, Healthians, and Dr. Lal PathLabs. This appointment follows the resignation of Dr. Anand K. Fortis Healthcare's MD & CEO, Dr. Ashutosh Raghuvanshi, expressed confidence in Singh's ability to drive Agilus's next phase of growth and innovation.

Fortis Healthcare Ltd has announced the fixation of the record date as Friday, July 24, 2026, for the payment of a final dividend of ₹1 per equity share for the financial year 2025-26. This dividend is subject to member approval at the 30th Annual General Meeting (AGM) scheduled for Tuesday, August 11, 2026. The Register of Members and Share Transfer Books will be closed from Saturday, July 25, 2026, to Tuesday, August 11, 2026, inclusive, for dividend payment and the AGM. The dividend will be paid within 30 days of the AGM, after deducting applicable taxes.

Fortis Healthcare Ltd has announced July 24, 2026, as the record date for the payment of a final dividend of ₹1 per equity share for the financial year 2025-26. This dividend, recommended by the Board of Directors, is subject to shareholder approval at the 30th Annual General Meeting (AGM) scheduled for August 11, 2026. The dividend will be paid within 30 days of the AGM, after applicable tax deductions. The Register of Members and Share Transfer Books will be closed from July 25, 2026, to August 11, 2026, inclusive, for both dividend payment and the AGM.

Fortis Healthcare Ltd has informed shareholders that letters containing a weblink to access the Annual Report and AGM Notice for FY 2025-2026 have been dispatched. This communication is specifically for shareholders whose email addresses are not registered with the company, RTA, or DPs. The Annual Report and AGM Notice are also available on the company's website. The 30th AGM is scheduled for August 11, 2026, to be held via Video Conference/OAVM. Shareholders can update their details through their DPs or the RTA, KFin Technologies Limited.